Incyte Corporation

INCY · NASDAQ · USD

Analysis

Last 4 earnings calls · through Q2 FY2026

Incyte is spending hard to stop being a one-drug company. Sales outside Jakafi are growing fast enough to replace it by 2030, but the pipeline carrying that hope now rests on a handful of late-stage bets.How much of INCY's 2030 growth target comes from products not yet approved?

  • The business outside Jakafi is now the growth engine.

    Ex-Jakafi sales rose 44% in Q2 FY2026 excluding a one-time legal benefit, and management now targets $3-4 billion from that book by 2030. Four launches in twelve months show it can scale several products at once, not just one.Which of INCY's new products should grow fastest through 2030?

  • Management is spending now to buy the next decade.

    2026 operating expenses were raised by about $1.3 billion, almost all the upfront cost of the Vega deal, and R&D is up roughly 10% as more late-stage trials begin. The cash is there, but the cost lands years before the sales it pays for.How much of INCY's higher 2026 spending is the one-time Vega payment?

  • The pipeline is narrower than the trial count suggests.

    Management shelved several programs this year and paused Opzelura in prurigo nodularis after the FDA asked for another trial. The future rides on a few assets, so one late-stage failure hurts more than the long trial list implies.

Bullish
  • Core products outside Jakafi
    The bull case is that Opzelura, Niktimvo and the hematology-oncology products are growing fast enough to cover Jakafi's eventual decline.
  • Late stage pipeline breadth
    Bulls point to a pipeline spanning myeloproliferative disease, dermatology and three solid-tumor programs, so no single trial failure ends the story.
  • Full year guidance raised
    Management has raised its own sales outlook and expects operating expense growth to stay below sales growth as launches scale up.
Bearish
  • Jakafi patent expiry
    Bears argue that Jakafi still supplies most of the revenue and that generic filings mean the largest single source of cash starts shrinking as its patent expires.
  • Pipeline setbacks and delays
    The bear case is that Incyte has already shelved several programs, and the ones still standing face regulatory negotiation and trial risk before they sell anything.
  • Pricing pressure on medicines
    Government pricing policy and payer pressure could limit how much the new products earn even if they are approved and launched on schedule.
See the full bull & bear case
PoliticiansInstitutionsInsiders
PoliticianTransactionAmountTradedFiled
Ro Khanna
Democratic · House · CA-17
Purchase≥$1KMay 15Jun 9
Ro Khanna
Democratic · House · CA-17
Purchase≥$1KMar 30Apr 7
Ro Khanna
Democratic · House · CA-17
Sale≥$1KMar 10Apr 7
Ro Khanna
Democratic · House · CA-17
Purchase≥$1KJan 29Feb 6
Ro Khanna
Democratic · House · CA-17
Purchase≥$1KMay 19Jun 10

Congressional trading data provided by QuiverQuant

See all
Product segmentsGeography
FY2025 · USD

How Incyte turned $5.1B of revenue into $1.5B of operating income.

Revenue
J A K A F I$3.6B▲ 10.57% YoY
OPZELURA$678.5M▲ 33.48% YoY
Milestone And Contract Revenue$150.0M▲ 248.84% YoY
Olumiant Royalty$144.6M▲ 6.66% YoY
M I N J U V I$144.6M▲ 21.25% YoY
I C L U S I G$134.1M▲ 17.28% YoY
PEMAZYRE Royalty Revenues$86.7M▲ 3.35% YoY
ZYNYZ$66.4M▲ 1983.23% YoY
Tabrecta Royalty Revenues$26.7M▲ 17.39% YoY
Total revenue$5.1B
Gross profit$4.8B92.8%
Operating income$1.5B29.5%
See all